397 related articles for article (PubMed ID: 33361336)
1. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma.
Neelapu SS; Adkins S; Ansell SM; Brody J; Cairo MS; Friedberg JW; Kline JP; Levy R; Porter DL; van Besien K; Werner M; Bishop MR
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33361336
[TBL] [Abstract][Full Text] [Related]
2. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer.
Galsky MD; Balar AV; Black PC; Campbell MT; Dykstra GS; Grivas P; Gupta S; Hoimes CJ; Lopez LP; Meeks JJ; Plimack ER; Rosenberg JE; Shore N; Steinberg GD; Kamat AM
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34266883
[TBL] [Abstract][Full Text] [Related]
3. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events.
Brahmer JR; Abu-Sbeih H; Ascierto PA; Brufsky J; Cappelli LC; Cortazar FB; Gerber DE; Hamad L; Hansen E; Johnson DB; Lacouture ME; Masters GA; Naidoo J; Nanni M; Perales MA; Puzanov I; Santomasso BD; Shanbhag SP; Sharma R; Skondra D; Sosman JA; Turner M; Ernstoff MS
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34172516
[TBL] [Abstract][Full Text] [Related]
4. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer.
Emens LA; Adams S; Cimino-Mathews A; Disis ML; Gatti-Mays ME; Ho AY; Kalinsky K; McArthur HL; Mittendorf EA; Nanda R; Page DB; Rugo HS; Rubin KM; Soliman H; Spears PA; Tolaney SM; Litton JK
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34389617
[TBL] [Abstract][Full Text] [Related]
5. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma.
Greten TF; Abou-Alfa GK; Cheng AL; Duffy AG; El-Khoueiry AB; Finn RS; Galle PR; Goyal L; He AR; Kaseb AO; Kelley RK; Lencioni R; Lujambio A; Mabry Hrones D; Pinato DJ; Sangro B; Troisi RI; Wilson Woods A; Yau T; Zhu AX; Melero I
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34518290
[TBL] [Abstract][Full Text] [Related]
6. The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia.
Boyiadzis MM; Aksentijevich I; Arber DA; Barrett J; Brentjens RJ; Brufsky J; Cortes J; De Lima M; Forman SJ; Fuchs EJ; Fukas LJ; Gore SD; Litzow MR; Miller JS; Pagel JM; Waller EK; Tallman MS
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33077513
[TBL] [Abstract][Full Text] [Related]
7. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer.
Silk AW; Barker CA; Bhatia S; Bollin KB; Chandra S; Eroglu Z; Gastman BR; Kendra KL; Kluger H; Lipson EJ; Madden K; Miller DM; Nghiem P; Pavlick AC; Puzanov I; Rabinowits G; Ruiz ES; Sondak VK; Tavss EA; Tetzlaff MT; Brownell I
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35902131
[TBL] [Abstract][Full Text] [Related]
8. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma.
Govindan R; Aggarwal C; Antonia SJ; Davies M; Dubinett SM; Ferris A; Forde PM; Garon EB; Goldberg SB; Hassan R; Hellmann MD; Hirsch FR; Johnson ML; Malik S; Morgensztern D; Neal JW; Patel JD; Rimm DL; Sagorsky S; Schwartz LH; Sepesi B; Herbst RS
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35640927
[TBL] [Abstract][Full Text] [Related]
9. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer.
Disis ML; Adams SF; Bajpai J; Butler MO; Curiel T; Dodt SA; Doherty L; Emens LA; Friedman CF; Gatti-Mays M; Geller MA; Jazaeri A; John VS; Kurnit KC; Liao JB; Mahdi H; Mills A; Zsiros E; Odunsi K
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37295818
[TBL] [Abstract][Full Text] [Related]
10. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.
Puzanov I; Diab A; Abdallah K; Bingham CO; Brogdon C; Dadu R; Hamad L; Kim S; Lacouture ME; LeBoeuf NR; Lenihan D; Onofrei C; Shannon V; Sharma R; Silk AW; Skondra D; Suarez-Almazor ME; Wang Y; Wiley K; Kaufman HL; Ernstoff MS;
J Immunother Cancer; 2017 Nov; 5(1):95. PubMed ID: 29162153
[TBL] [Abstract][Full Text] [Related]
11. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events.
Maus MV; Alexander S; Bishop MR; Brudno JN; Callahan C; Davila ML; Diamonte C; Dietrich J; Fitzgerald JC; Frigault MJ; Fry TJ; Holter-Chakrabarty JL; Komanduri KV; Lee DW; Locke FL; Maude SL; McCarthy PL; Mead E; Neelapu SS; Neilan TG; Santomasso BD; Shpall EJ; Teachey DT; Turtle CJ; Whitehead T; Grupp SA
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33335028
[TBL] [Abstract][Full Text] [Related]
12. Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology.
Naidoo J; Murphy C; Atkins MB; Brahmer JR; Champiat S; Feltquate D; Krug LM; Moslehi J; Pietanza MC; Riemer J; Robert C; Sharon E; Suarez-Almazor ME; Suresh K; Turner M; Weber J; Cappelli LC
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 37001909
[TBL] [Abstract][Full Text] [Related]
13. Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease.
Luke JJ; Davar D; Andtbacka RH; Bhardwaj N; Brody JD; Chesney J; Coffin R; de Baere T; de Gruijl TD; Fury M; Goldmacher G; Harrington KJ; Kaufman H; Kelly CM; Khilnani AD; Liu K; Loi S; Long GV; Melero I; Middleton M; Neyns B; Pinato DJ; Sheth RA; Solomon SB; Szapary P; Marabelle A
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38641350
[TBL] [Abstract][Full Text] [Related]
14. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia.
Boyiadzis M; Bishop MR; Abonour R; Anderson KC; Ansell SM; Avigan D; Barbarotta L; Barrett AJ; Van Besien K; Bergsagel PL; Borrello I; Brody J; Brufsky J; Cairo M; Chari A; Cohen A; Cortes J; Forman SJ; Friedberg JW; Fuchs EJ; Gore SD; Jagannath S; Kahl BS; Kline J; Kochenderfer JN; Kwak LW; Levy R; de Lima M; Litzow MR; Mahindra A; Miller J; Munshi NC; Orlowski RZ; Pagel JM; Porter DL; Russell SJ; Schwartz K; Shipp MA; Siegel D; Stone RM; Tallman MS; Timmerman JM; Van Rhee F; Waller EK; Welsh A; Werner M; Wiernik PH; Dhodapkar MV
J Immunother Cancer; 2016; 4():90. PubMed ID: 28018601
[TBL] [Abstract][Full Text] [Related]
15. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer.
Kelly RJ; Bever K; Chao J; Ciombor KK; Eng C; Fakih M; Goyal L; Hubbard J; Iyer R; Kemberling HT; Krishnamurthi S; Ku G; Mordecai MM; Morris VK; Paulson AS; Peterson V; Shah MA; Le DT
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37286304
[TBL] [Abstract][Full Text] [Related]
16. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0.
Pavlick AC; Ariyan CE; Buchbinder EI; Davar D; Gibney GT; Hamid O; Hieken TJ; Izar B; Johnson DB; Kulkarni RP; Luke JJ; Mitchell TC; Mooradian MJ; Rubin KM; Salama AK; Shirai K; Taube JM; Tawbi HA; Tolley JK; Valdueza C; Weiss SA; Wong MK; Sullivan RJ
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37852736
[TBL] [Abstract][Full Text] [Related]
17. Development of preclinical and clinical models for immune-related adverse events following checkpoint immunotherapy: a perspective from SITC and AACR.
Bayless NL; Bluestone JA; Bucktrout S; Butterfield LH; Jaffee EM; Koch CA; Roep BO; Sharpe AH; Murphy WJ; Villani AC; Walunas TL
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34479924
[TBL] [Abstract][Full Text] [Related]
18. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC).
Cohen EEW; Bell RB; Bifulco CB; Burtness B; Gillison ML; Harrington KJ; Le QT; Lee NY; Leidner R; Lewis RL; Licitra L; Mehanna H; Mell LK; Raben A; Sikora AG; Uppaluri R; Whitworth F; Zandberg DP; Ferris RL
J Immunother Cancer; 2019 Jul; 7(1):184. PubMed ID: 31307547
[TBL] [Abstract][Full Text] [Related]
19. Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation.
Masucci GV; Cesano A; Hawtin R; Janetzki S; Zhang J; Kirsch I; Dobbin KK; Alvarez J; Robbins PB; Selvan SR; Streicher HZ; Butterfield LH; Thurin M
J Immunother Cancer; 2016; 4():76. PubMed ID: 27895917
[TBL] [Abstract][Full Text] [Related]
20. From a Patient Advocate's Perspective: Does Cancer Immunotherapy Represent a Paradigm Shift?
Madden DL
Curr Oncol Rep; 2018 Feb; 20(1):8. PubMed ID: 29411148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
